SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories reports 57% growth in Q3FY17 net profit

10 Feb 2017 Evaluate

Ipca Laboratories has reported results for third quarter ended December 31, 2016. 

The company has reported 57.22% rise in its net profit at Rs 41.38 crore for the quarter under review as compared to Rs 26.32 crore for the same quarter in the previous year. Total income of the company increased by 8.23% at Rs 756.66 crore for the quarter under review as compared to Rs 699.13 crore for the corresponding quarter previous year.

Ipca is a fully integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments. For more than 60 years, Ipca has been partnering healthcare globally in over 110 countries and in markets as diverse as Africa, Asia, Australia, Europe and the US.

Ipca Laboratories Share Price

1563.70 19.75 (1.28%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.40
Dr. Reddys Lab 1310.50
Cipla 1365.25
Zydus Lifesciences 939.10
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×